BLOOD MONITORING, REIMAGINED

Introducing Sight OLO® brought to you by AASPIRE

Fast, convenient, and accurate blood monitoring at the point of care

AA-Pharma is proud to partner with Sight Diagnostics® to exclusively bring OLO to your patients on AA-Clozapine.

Intended for audiences in Canada only.

AA-Clozapine (clozapine) is indicated in the management of symptoms of treatment-resistant schizophrenia.¹
Reliable blood monitoring at your fingertips

OLO is licenced in Canada for performing CBC tests at the point of care.*

OLO is a high-performance CBC analyzer. It delivers lab-grade results in minutes from 2 drops of blood obtained from 1 finger prick sample.²

Connectivity to LIS or middleware or directly to EHR/EMR enables seamless and secure integration of information to:

- AASPIRE
- The patient's electronic record

---

* Sight OLO is licensed by Health Canada as a Class III device ( Licence No.: 106263).

CBC, complete blood count; EHR, electronic health record; EMR, electronic medical record; LIS, laboratory information system.
Just 1 finger prick and 2 drops of blood

With OLO, routine bloodwork is simple and convenient, so you and your patients on AA-Clozapine have one less thing to worry about.

OLO simplifies required blood monitoring with:

- **Point-of-care use**
  - On-site blood monitoring means real-time clinical decisions, with less hassle for your patients

- **Direct-from-finger prick testing**
  - Quick and less invasive than venipuncture
  - Removes one of the most common barriers to clozapine therapy

- **Just 2 drops of blood (27 μL)**
  - Requires only 5% of the minimum blood volume needed for traditional lab-based testing methods

- **Rapid results**
  - Actionable results are ready in minutes, enabling you to make faster treatment decisions for optimal patient care
Simple to set up and operate

OLO comes factory-calibrated for quick set-up and requires no routine maintenance or manual quality control (QC). With step-by-step onscreen guidance, it is designed to be easy for anyone to use.*

Easy to install
- Initial installation of OLO will be performed by our team
- Factory-calibrated for quick set-up

Easy to use
- Minimal training required
- Step-by-step touchscreen instructions
- Internal failsafe system ensures integrity of results

Easy to maintain
- No maintenance or manual calibration for users
- No reagent management
- Remote support and servicing to reduce unnecessary downtime

* The device is intended to be operated by users trained on the use of the Sight OLO.
Better patient experience, better patient care in 3 easy steps

1. Collect finger prick sample
   Add 2 drops of capillary blood to the OLO single-use cartridge. The sample preparation process takes less than a minute.

2. Analyze with OLO
   Insert the cartridge into OLO and wait for the machine-vision scanning to be performed.

3. View results
   Full results are ready in minutes via touchscreen interface, printout, or email. View the results and transfer data to AASPIRE, The AA-Clozapine Patient Care Network, and your patient’s electronic record.

Works for patients
Testing is less painful, non-invasive, and convenient, reducing the impact of required blood monitoring on your patient’s quality of life.

Works for you
Reliable, real-time results empower you to make quick and informed treatment decisions.
Proven lab-grade results without the lab

OLO combines cutting-edge digital microscopy and artificial intelligence algorithms to deliver no-compromise CBC results.²

Comprehensive
OLO generates the full breadth of CBC test results:²

19 measured parameters⁴
• Performs a robust hematological analysis to support clinical decision-making

5-part differential⁴
• Reports the differential count (including ANC) required to initiate or continue treatment with AA-Clozapine¹

Sophisticated flagging capabilities⁴
• Detects and flags results that may be affected by abnormal cell morphology or other interferences

Extensive reportable and display range²
• Quantifies and reports CBC results across a wide range that covers the WBC count and ANC values relevant to patients on AA-Clozapine¹

<table>
<thead>
<tr>
<th>CBC parameters⁴</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>WBC</td>
<td>White Blood Cell Count</td>
</tr>
<tr>
<td>RBC</td>
<td>Red Blood Cell Count</td>
</tr>
<tr>
<td>HGB</td>
<td>Hemoglobin</td>
</tr>
<tr>
<td>HCT</td>
<td>Hematocrit</td>
</tr>
<tr>
<td>MCV</td>
<td>Mean Corpuscular Volume</td>
</tr>
<tr>
<td>MCH</td>
<td>Mean Corpuscular Hemoglobin</td>
</tr>
<tr>
<td>MCHC</td>
<td>Mean Corpuscular Hemoglobin Concentration</td>
</tr>
<tr>
<td>RDW</td>
<td>Red Blood Cell Distribution Width</td>
</tr>
<tr>
<td>PLT</td>
<td>Platelet Count</td>
</tr>
<tr>
<td>NEUT%/#</td>
<td>Neutrophil Percent and Count</td>
</tr>
<tr>
<td>LYMPTH%/#</td>
<td>Lymphocyte Percent and Count</td>
</tr>
<tr>
<td>MONO%/#</td>
<td>Monocyte Percent and Count</td>
</tr>
<tr>
<td>EO%/#</td>
<td>Eosinophil Percent and Count</td>
</tr>
<tr>
<td>BASO%/#</td>
<td>Basophil Percent and Count</td>
</tr>
</tbody>
</table>

ANC, absolute neutrophil count; CBC, complete blood count; WBC, white blood cell.
Accurate

OLO provides CBC results that match best-in-class laboratory equipment. The Health Canada approval of OLO is based on substantially equivalent data comparing OLO to Sysmex XN™.*

**White blood cells**

![WBC count – OLO vs. XN²](image)

*WBC count – OLO vs. XN²*

$r = 0.997$ (N=608)

**Passing-Bablok regression – WBC count (all sites combined)**

Based on data from comparison studies performed at 3 US sites to evaluate OLO vs. a lab reference device (Sysmex XN™).

**Neutrophils**

![NEUT count – OLO vs. XN²](image)

*NEUT count – OLO vs. XN²*

$r = 0.995$ (N=412)

**Passing-Bablok regression – NEUT count (all sites combined)**

Based on data from comparison studies performed at 3 US sites to evaluate OLO vs. a lab reference device (Sysmex XN™).


* All other trademarks are the property of their respective owners.

CBC, complete blood count; NEUT, neutrophil; WBC, white blood cell.
SIGHT OLO BROUGHT TO YOU BY AASPIRE. IT JUST WORKS.

References:

Sight OLO is a registered trademark of Sight Diagnostics.
© 2021 Sight Diagnostics Ltd., All rights reserved.
AA Pharma Inc. All rights reserved.